Amphastar Pharmaceuticals NASDAQ: AMPH executives said the company is taking steps to address rebate and discounting pressure on BAQSIMI while maintaining its full-year revenue outlook, according to remarks at the BofA Annual Healthcare Conference.
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript
| Specialty Retail Industry | Consumer Discretionary Sector | Yongfeng Zhang CEO | XFRA Exchange | US03209R1032 ISIN |
| US Country | 2,028 Employees | - Last Dividend | - Last Split | - IPO Date |
Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company that focuses on the development, manufacturing, marketing, and sale of both generic and proprietary injectable, inhalation, and intranasal products. The company has a global footprint with operations in the United States, China, and France. Established in 1996 and based in Rancho Cucamonga, California, Amphastar Pharmaceuticals caters to a diverse range of medical needs, emphasizing solutions for severe hypoglycemia, opioid overdose, adrenocortical insufficiency, intermittent asthma, and deep vein thrombosis among others. Additionally, the company engages in the distribution of insulin APIs and is involved in the development of generic, biosimilar, and innovative analytical technologies.